The D-day has finally been revealed. Will the lung cancer treatment ‘Tagrisso’ finally succeed in extending reimbursement to the first line?

According to industry sources, AstraZeneca’s EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment Tagrisso will be deliberated at the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee meeting on March 22.

A dire need had long existed. The public petition urging for the extension of reimbursement benefits to the first line for Tagrisso that had been filed earlier this year had received consent from 50,000 people. Patients desperately want it, but doctors are saying no to it. Under such strange